Biotech IV Monitor

EXEL — Exelixis Inc.

$13.5B market cap · 7 upcoming readouts tracked

Clinical trial readout dates for Exelixis Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts75 Phase 3
Market cap$13.5B
Cash & investments$1.52Bas of Oct 2, 2026
Recent 8-K filings1latest 2026-10-29

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 3 XL092
Colorectal Cancer · NCT05425940
June 2026
Primary data collected

Upcoming readouts

Phase 3 XL092
Non-Clear Cell Renal Cell Carcinoma · NCT05678673
December 2026
Ongoing
Phase 2 Zanzalintinib
Meningioma · NCT07428616
February 2028
Recruiting
Phase 2 Carboplatin
Squamous Non-Small Cell Lung Cancer (NSCLC) · NCT07845786
June 2028
Recruiting
Phase 2/3 Zanzalintinib
Head and Neck Squamous Cell Carcinoma · NCT06082167
August 2028
Ongoing
Phase 2/3 Zanzalintinib
Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET) · NCT06943755
June 2029
Recruiting
Phase 3 Zanzalintinib
Colorectal Cancer · NCT07750158
April 2030
Recruiting
Phase 3 Cabozantinib
Cancer; Renal Cell Carcinoma (RCC) · NCT07620574
May 2030
Enrolling

Cash position

Exelixis Inc. reported $1.52B in cash, cash equivalents and marketable securities at Oct 2, 2026 (10-Q filed 2026-10-29). It reported net income of $218M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-10-29

Companies working on similar indications

Discussion

No messages yet. If you follow EXEL, you can start the conversation.
Track EXEL in real time
See live implied volatility for EXEL and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on EXEL
Contact — questions or corrections about EXEL: dukeupt@gmail.com